Edesa Biotech Raises $3.5M in PIPE, Prices Shares at $4.69 and $5.21 Each
EDSA•Edesa Biotech has agreed a $3.5M PIPE financing selling 729,241 common shares at $4.69 per share for investors and $5.21 per share for its CEO, expected to close June 15, 2026. The company plans to use net proceeds to advance its vitiligo antibody EB06 and candidate paridiprubart, bolstering working capital.
1. PIPE Financing Terms
Edesa Biotech entered into a securities purchase agreement to raise approximately $3.5 million through a private placement of 729,241 common shares. Shares were priced at $4.69 each for healthcare-focused investors and $5.21 each for the CEO, with no underwriter or broker involved.
2. Closing Timeline and Conditions
The financing is expected to close on or about June 15, 2026, subject to customary closing conditions. Edesa has agreed to file a registration statement covering the resale of the shares within 45 days of closing, and Canadian hold periods will apply to securities issued locally.
3. Planned Use of Proceeds
Net proceeds from the PIPE will fund continued advancement of EB06, an anti-CXCL10 monoclonal antibody for vitiligo, support development of paridiprubart, and provide working capital and general corporate resources.
